ID: ALA2326864

Max Phase: Preclinical

Molecular Formula: C14H17N5OS

Molecular Weight: 303.39

Molecule Type: Small molecule

Representations

Canonical SMILES:  CC(=O)Nc1nc(CCc2ccc(NC(=N)N)cc2)cs1

Standard InChI:  InChI=1S/C14H17N5OS/c1-9(20)17-14-19-12(8-21-14)7-4-10-2-5-11(6-3-10)18-13(15)16/h2-3,5-6,8H,4,7H2,1H3,(H4,15,16,18)(H,17,19,20)

Standard InChI Key:  LMDXCMJWFMSUAI-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 303.39

Molecular Weight (Monoisotopic): 303.1154

AlogP: 2.19

#Rotatable Bonds: 5

Polar Surface Area: 103.89

Molecular Species: BASE

HBA: 4

HBD: 4

#RO5 Violations: 0

HBA (Lipinski): 6

HBD (Lipinski): 5

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 7.97

CX Basic pKa: 8.95

CX LogP: 1.16

CX LogD: 0.80

Aromatic Rings: 2

Heavy Atoms: 21

QED Weighted: 0.50

Np Likeness Score: -1.49

References

1. Inoue T, Morita M, Tojo T, Yoshihara K, Nagashima A, Moritomo A, Ohkubo M, Miyake H..  (2013)  Synthesis and SAR study of new thiazole derivatives as vascular adhesion protein-1 (VAP-1) inhibitors for the treatment of diabetic macular edema.,  21  (5): [PMID:23337801] [10.1016/j.bmc.2012.12.025]

2. Inoue T, Morita M, Tojo T, Nagashima A, Moritomo A, Miyake H..  (2013)  Novel 1H-imidazol-2-amine derivatives as potent and orally active vascular adhesion protein-1 (VAP-1) inhibitors for diabetic macular edema treatment.,  21  (13): [PMID:23664164] [10.1016/j.bmc.2013.04.011]

3. Mark Wenlock and Nicholas Tomkinson. Experimental in vitro DMPK and physicochemical data on a set of publicly disclosed compounds,  [10.6019/CHEMBL3301361]

Source

Source(2):

• Scientific Literature
• AstraZeneca Deposited Data